Semaglutide → thyroid cancer — Null result

← All findings ⬇ Download signed audit packet

Ledger entry · null-result

Semaglutide → thyroid cancer — Null result

Drug: semaglutide · AE: thyroid cancer

Caliper validation of the submitted claim (drug=semaglutide, AE=thyroid cancer). BELOW_PRR_THRESHOLD — disproportionality not significant (PRR=1.44, lower CI=1.00)

Disproportionality

PRR: 1.4442300212428567 (95% CI 1.00–2.08)
Yates χ²: 3.526349685089883
Cases (case-drug + AE): n = 29
Verdict: BELOW_PRR_THRESHOLD — disproportionality not significant (PRR=1.44, lower CI=1.00)

Top reactions in cohort

MedDRA PT	n
Thyroid cancer	25
Thyroid mass	2
Fatigue	1
Gastrooesophageal reflux disease	1
Incorrect dose administered	1
Off label use	1
Product use in unapproved indication	1
Swelling	1

Source: openFDA FAERS, Caliper Engine v0. Pre-registration sha1 locked at submission time; ledger entry signed with platform Ed25519 key.

Independent Verification & Validation

Every finding includes an in-engine adversary review at no cost. For findings you plan to cite in a regulatory submission, scientific publication, or board-grade decision, we offer an additional layer of independent, audit-grade verification — reviewed by an externally-trained system that has never seen your data, your training corpus, or our hardware, and cryptographically signed.

Reference: b25d8cde3fad9bfe0ca9250d20ad65fb6ece1a4e